ArticleAmerican journal of translational research2025
Assessing the role of LRRCl5 as a prognostic and therapeutic biomarker in glioblastoma.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGlioblastoma (GBM) is the most aggressive primary brain tumor, characterized by rapid progression and poor prognosis. Identifying novel biomarkers and therapeutic targets is crucial for improving GBM outcomes. This study aimed to explore the expression, prognostic value, therapeutic significance, and functional role of Leucine-Rich Repeat Containing 15 (LRRC15) in GBM.
methodsWe utilized data from multiple online databases to analyze LRRC15 expression and its prognostic significance. Mutational and methylation profiles were examined, followed by survival analyses. Experimental validation was conducted using reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blotting in GBM cell lines. Functional assays, including colony formation, proliferation, and wound healing, were used to assess the effects of LRRC15 knockdown.
resultsLRRC15 expression was significantly elevated in GBM. High LRRC15 levels were associated with shorter overall survival (OS) and disease-free survival (DFS) in GBM patients. Methylation analysis indicated that promoter hypermethylation may regulate LRRC15 expression. Knockdown of LRRC15 in GBM cell lines led to reduced cell proliferation, colony formation, and migration, along with a reversal of epithelial-mesenchymal transition (EMT), characterized by decreased N-cadherin and vimentin and increased E-cadherin expression.
conclusionLRRC15 is highly expressed in GBM and correlates with poor patient prognosis. Its role in enhancing cell proliferation, migration, and EMT suggests that LRRC15 contributes to GBM aggressiveness. These findings highlight LRRC15 as a promising biomarker and potential therapeutic target for GBM, warranting further investigation into LRRC15-targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.